

JUL 1 2002

Neuron Therapeutics, Inc.  
14-Gauge Lumbar Puncture Set  
510(k)

12 April 2002

K021196

**SECTION 9: 510 (k) SUMMARY (FFD&C ACT 513(I)(3)(A))**



**Summary of Safety and Effectiveness Data  
NEURON THERAPEUTICS INC., 14-GAUGE LUMBAR PUNCTURE SET  
12 April 2002**

Neuron Therapeutics, Inc.  
81 Great Valley Parkway  
Malvern, PA 19355

**Contact Person** \_\_\_\_\_

Judy P. Ways, Ph.D.  
Vice President, Regulatory Affairs and Quality Assurance  
Phone: (610) 578-9494 x112  
Fax: (610) 578-9205

**Name of Device** \_\_\_\_\_

Proprietary Name: Neuron Therapeutics, Inc., 14-Gauge Lumbar Puncture Set  
Trade Name: 14-Gauge Lumbar Puncture Set  
Common Name: Sterile, 14-Gauge Lumbar Puncture Set  
Classification Name: Central Nervous System Fluid Shunt and Components  
Regulatory Class: II (21CFR § 882.5550)  
Product Code: 84 JXG  
Establishment Registration Number: 9001269

### **Device Classification**

---

This device has been placed in a Class II for Central Nervous System shunt and components per 21 CFR § 882.5550.

### **Statement of Substantial Equivalence**

---

The 14-Gauge Lumbar Catheter is the component of the 14-Gauge Lumbar Puncture Set subject to 510(k) approval. Neuron Therapeutic Inc.'s (NTI) 14-Gauge Lumbar Catheter is substantially equivalent to the CODMAN Lumbar External Drainage Catheter with Touhy Needle that is currently marketed in the United States under 510(k) No. K964923. NTI's 14-Gauge Lumbar Catheter and 14-Gauge Lumbar Puncture Set have the same intended use, design characteristics, and similar methods of manufacture as the CODMAN Lumbar External Drainage Catheter with Touhy Needle.

### **Indications for Use**

---

The Neuron Therapeutics Inc., 14-Gauge Lumbar Puncture Set has an substantially equivalent indication for use as the Codman Lumbar Drainage Catheter Kit. Both are indicated for temporary access to the lumbar subarachnoid region to drain cerebrospinal fluid (CSF) and other fluids of similar physical characteristics.

### **Physical Description**

---

The Neuron Therapeutics 14-Gauge Lumbar Puncture Set, part number PN1000735, consists of a 14-Gauge Lumbar Catheter Kit, a Transparent Tegaderm™ Dressing, a Suture-less Catheter Anchor, and a Sterile Drape. These individual, sterile packaged components are provided in sealed tamper-evident packaging for single-use.

The 14-Gauge Lumbar Catheter Kit, part number PN1000737, contains a single 30 cm coiled lumbar catheter with an inner diameter of 1.25 mm, an outer diameter of 1.74 mm and 35 fenestrations. The shorter length, larger diameter and higher number of fenestrations of the catheter allow for decreased flow resistance and higher liquid flow rates. The higher number of fenestrations decreases the possibility of occlusion of the catheter during use. The catheter is constructed of polyurethane to provide resistance to kinking or collapsing. The catheter has 13 location markings positioned at 1 cm intervals to assist the physician in identifying the location of the distal end of the catheter in the subarachnoid space. Special

markings are provided to indicate the location of the catheter tip, the proximal fenestration and the coiled shaft as they exit from the needle tip.

The 14-Gauge Lumbar Catheter Kit also contains a 15.0 cm, 14-gauge Extra-Thin Wall Touhy Needle and a 45 cm stainless steel flexible J-tip guidewire for inserting and guiding the catheter into the lumbar subarachnoid space. A 6-French Touhy-Borst Connector is also included for connection to equipment for patient monitoring or fluid collection.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUL 1 2002

Neuron Therapeutics, Inc.  
Judy P. Ways, Ph.D.  
Vice President, Regulatory Affairs and Quality Assurance  
81 Great Valley Parkway  
Malvern, Pennsylvania 19355

Re: K021196

Trade Name: Neuron Therapeutics, Inc., 14-Gauge Lumbar Puncture Set  
Regulation Number: 882.5550  
Regulation Name: Central nervous system fluid shunt and components  
Regulatory Class: II  
Product Code: JXG  
Dated: April 12, 2002  
Received: April 16, 2002

Dear Dr. Ways:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Dr. Judy Ways

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is written in a cursive style with a large initial "C".

Celia M. Witten, Ph.D., M.D.

Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

